Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose metformin in dialysis patients with type 2 diabetes
ACTRN12616000675426Phase 4Terminated
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin in type 2 diabetes mellitus (T2DM) and end-stage kidney disease (ESKD) (3 arms), sponsored by St Vincent's Hospital Sydney. Primary endpoint: Safety of metformin in patients undergoing haemodialysis. Started Jul 2014; status: terminated.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ACTRN12616000675426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000675426.